Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 4/2020

01-04-2020 | Radiotherapy | Review Article

Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy

Authors: M. Protopapa, V. Kouloulias, A. Kougioumtzopoulou, Z. Liakouli, C. Papadimitriou, A. Zygogianni

Published in: Clinical and Translational Oncology | Issue 4/2020

Login to get access

Abstract

Radiation acts not only through cell death but has also angiogenic, immunomodulatory and bystander effects. The realization of its systemic implications has led to extensive research on the combination of radiotherapy with systemic treatments, including immunotherapy and antiangiogenic agents. Parameters such as dose, fractionation and sequencing of treatments are key determinants of the outcome. However, recent high-quality research indicates that these are not the only radiation therapy parameters that influence its systemic effect. To effectively integrate systemic agents with radiation therapy, these new aspects of radiation therapy planning will have to be taken into consideration in future clinical trials. Our aim is to review these new treatment planning parameters that can influence the balance between contradicting effects of radiation therapy so as to enhance the therapeutic ratio.
Literature
1.
Pouget J-P, Frelon S, Ravanat J-L, Testard I, Odin F, Cadet J. Formation of modified DNA bases in cells exposed either to gamma radiation or to high-LET particles. Radiat Res. 2002;157:589–95.PubMed
2.
Rothkamm K, Löbrich M. Misrepair of radiation-induced DNA double-strand breaks and its relevance for tumorigenesis and cancer treatment. Int J Oncol. 2002;21:433–40 (Review).PubMed
3.
Foray N, Arlett CF, Malaise EP. Radiation-induced DNA double-strand breaks and the radiosensitivity of human cells: a closer look. Biochimie. 1997;79:567–75.PubMed
4.
Ceccaldi R, Rondinelli B, D’Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016;26:52–64.PubMed
5.
Kellerer AM, Rossi HH. A generalized formulation of dual radiation action. Radiat Res. 1978;75:471.
6.
Chadwick KH, Leenhouts HP. A molecular theory of cell survival. Phys Med Biol. 1973;18:007.
7.
Brenner DJ. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol. 2008;18:234–9.PubMedPubMedCentral
8.
McMahon SJ. The linear quadratic model: usage, interpretation and challenges. Phys Med Biol. 2018;64:01TR01.PubMed
9.
Goldsmith C, Plowman PN, Green MM, Dale RG, Price PM. Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity. Radiat Oncol. 2018;13:204.PubMedPubMedCentral
10.
Stahl JM, Ross R, Harder EM, Mancini BR, Soulos PR, Finkelstein SE, Shafman TD, Dosoretz AP, Evans SB, Husain ZA, et al. The effect of biologically effective dose and radiation treatment schedule on overall survival in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol. 2016;96:1011–20.
11.
Herskind C, Ma L, Liu Q, Zhang B, Schneider F, Veldwijk MR, Wenz F. Biology of high single doses of IORT: RBE, 5 R’s, and other biological aspects. Radiat Oncol. 2017;12:24.PubMedPubMedCentral
12.
Chargari C, Van Limbergen E, Mahantshetty U, Deutsch É, Haie-Méder C. Radiobiology of brachytherapy: the historical view based on linear quadratic model and perspectives for optimization. Cancer Radiothér. 2018;22:312–8.PubMed
13.
Sherwood LM, Parris EE, Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.
14.
Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 1998;58:1408–16.PubMed
15.
Baker DG, Krochak RJ. The response of the microvascular system to radiation: a review. Cancer Invest. 1989;7:287–94.PubMed
16.
Rannou E, François A, Toullec A, Guipaud O, Buard V, Tarlet G, Mintet E, Jaillet C, Iruela-Arispe ML, Benderitter M, et al. In vivo evidence for an endothelium-dependent mechanism in radiation-induced normal tissue injury. Sci Rep. 2015;5:15738.PubMedPubMedCentral
17.
Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638–48.PubMed
18.
Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol. 2007;25:4066–74.PubMed
19.
Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012;177:311–27.PubMed
20.
Song CW, Lee Y-J, Griffin RJ, Park I, Koonce NA, Hui S, Kim M-S, Dusenbery KE, Sperduto PW, Cho LC. Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol. 2015;93:166–72.
21.
Dings RPM, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors Anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007;13:3395–402.PubMedPubMedCentral
22.
Kleibeuker EA, ten Hooven MA, Castricum KC, Honeywell R, Griffioen AW, Verheul HM, Slotman BJ, Thijssen VL. Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction. Cancer Med. 2015;4:1003–15.PubMedPubMedCentral
23.
Kleibeuker EA, Fokas E, Allen PD, Kersemans V, Griffioen AW, Beech J, Im JH, Smart SC, Castricum KC, van den Berg J, et al. Low dose angiostatic treatment counteracts radiotherapy-induced tumor perfusion and enhances the anti-tumor effect. Oncotarget. 2016;7:76613–27.PubMedPubMedCentral
24.
Janssen MHM, Aerts HJWL, Kierkels RGJ, Backes WH, Öllers MC, Buijsen J, Lambin P, Lammering G. Tumor perfusion increases during hypofractionated short-course radiotherapy in rectal cancer: sequential perfusion-CT findings. Radiother Oncol. 2010;94:156–60.PubMed
25.
Cooper RA, West CM, Logue JP, Davidson SE, Miller A, Roberts S, Statford IJ, Honess DJ, Hunter RD. Changes in oxygenation during radiotherapy in carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 1999;45:119–26.PubMed
26.
Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed Glioblastoma. N Engl J Med. 2014;370:709–22.PubMed
27.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al. A randomized trial of Bevacizumab for newly diagnosed Glioblastoma. N Engl J Med Am Coll Radiol Chic N Engl J Med. 2014;370(8):699–708.
28.
Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, Hu K, Le QT, Colevas AD, Glisson BS, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. Lancet Oncol. 2012;13:172–80.PubMed
29.
Kennecke H, Berry S, Wong R, Zhou C, Tankel K, Easaw J, Rao S, Post J, Hay J. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer. 2012;48:37–45.PubMed
30.
Landry JC, Feng Y, Prabhu RS, Cohen SJ, Staley CA, Whittington R, Sigurdson ER, Nimeiri H, Verma U, Benson AB. Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin, and Bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and Bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN cancer research group E3204. Oncologist. 2015;20:615–6.PubMedPubMedCentral
31.
Hamming LC, Slotman BJ, Verheul HMW, Thijssen VL. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis. 2017;20:217–32.PubMedPubMedCentral
32.
Oh E-T, Park M-T, Song M-J, Lee H, Cho YU, Kim SJ, Chu Y-C, Choi EK, Park HJ. Radiation-induced angiogenic signaling pathway in endothelial cells obtained from normal and cancer tissue of human breast. Oncogene. 2014;33:1229–38.PubMed
33.
Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5:429–41.PubMed
34.
Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8:579–91.PubMed
35.
Guzy RD, Schumacker PT. Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Exp Physiol. 2006;91:807–19.PubMed
36.
Sabharwal SS, Schumacker PT. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer. 2014;14:709–21.PubMedPubMedCentral
37.
Azimi I, Petersen RM, Thompson EW, Roberts-Thomson SJ, Monteith GR. Hypoxia-induced reactive oxygen species mediate N-cadherin and SERPINE1 expression, EGFR signalling and motility in MDA-MB-468 breast cancer cells. Sci Rep. 2017;7:15140.PubMedPubMedCentral
38.
Moeller BJ, Dreher MR, Rabbani ZN, Schroeder T, Cao Y, Li CY, Dewhirst MW. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell. 2005;8:99–110.PubMed
39.
Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell. 2005;8:89–91.PubMed
40.
Marathe S, Schissel SL, Yellin MJ, Beatini N, Mintzer R, Williams KJ, Tabas I. Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem. 1998;273:4081–8.PubMed
41.
Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300:1155–9.PubMed
42.
Toullec A, Buard V, Rannou E, Tarlet G, Guipaud O, Robine S, Iruela-Arispe ML, François A, Milliat F. HIF-1α deletion in the endothelium, but not in the epithelium, protects from radiation-induced enteritis. Cell Mol Gastroenterol Hepatol. 2018;5:15–30.PubMed
43.
Lavigne J, Suissa A, Verger N, Dos Santos M, Benadjaoud M, Mille-Hamard L, Momken I, Soysouvanh F, Buard V, Guipaud O, et al. Lung stereotactic arc therapy in mice: development of radiation pneumopathy and influence of HIF-1α endothelial deletion. Int J Radiat Oncol. 2019;104:279–90.
44.
Jaillet C, Morelle W, Slomianny M-C, Paget V, Tarlet G, Buard V, Selbonne S, Caffin F, Rannou E, Martinez P, et al. Radiation-induced changes in the glycome of endothelial cells with functional consequences. Sci Rep. 2017;7:5290.PubMedPubMedCentral
45.
Rodriguez-Ruiz ME, Garasa S, Rodriguez I, Solorzano JL, Barbes B, Yanguas A, Teijeira A, Etxeberria I, Aristu JJ, Halin C, et al. Intercellular adhesion molecule-1 and vascular cell adhesion molecule are induced by ionizing radiation on lymphatic endothelium. Int J Radiat Oncol. 2017;97:389–400.
46.
Soloviev AI, Kizub IV. Mechanisms of vascular dysfunction evoked by ionizing radiation and possible targets for its pharmacological correction. Biochem Pharmacol. 2019;159:121–39.PubMed
47.
Abuodeh Y, Venkat P, Kim S. Systematic review of case reports on the abscopal effect. Curr Probl Cancer. 2016;40:25–37.PubMed
48.
49.
Ko EC, Benjamin KT, Formenti SC. Generating antitumor immunity by targeted radiation therapy: role of dose and fractionation. Adv Radiat Oncol. 2018;3:486–93.PubMedPubMedCentral
50.
Buchwald ZS, Wynne J, Nasti TH, Zhu S, Mourad WF, Yan W, Gupta S, Khleif SN, Khan MK. Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation. Front Oncol. 2018;8:612.PubMedPubMedCentral
51.
Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer. 2018;18:313–22.PubMedPubMedCentral
52.
Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97–111.PubMed
53.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050–9.PubMed
54.
Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira J-P, Delaloge S, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev. 2007;220:47–59.PubMed
55.
Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M, Formenti SC. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death. Oncoimmunology. 2014;3:e28518.PubMedPubMedCentral
56.
Chen Q, Sun L, Chen ZJ. Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing. Nat Immunol. 2016;17:1142–9.PubMed
57.
Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li X-D, Mauceri H, Beckett M, Darga T, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity. 2014;41:843–52.PubMedPubMedCentral
58.
Fuertes MB, Kacha AK, Kline J, Woo S-R, Kranz DM, Murphy KM, Gajewski TF. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells. J Exp Med. 2011;208:2005–16.PubMedPubMedCentral
59.
Bakhoum SF, Ngo B, Laughney AM, Cavallo J-A, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553:467–72.PubMedPubMedCentral
60.
Liang H, Deng L, Hou Y, Meng X, Huang X, Rao E, Zheng W, Mauceri H, Mack M, Xu M, et al. Host STING-dependent MDSC mobilization drives extrinsic radiation resistance. Nat Commun. 2017;8:1736.PubMedPubMedCentral
61.
Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.PubMedPubMedCentral
62.
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259–71.PubMedPubMedCentral
63.
Foster CC, Sher DJ, Rusthoven CG, Verma V, Spiotto MT, Weichselbaum RR, Koshy M. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a national cancer database analysis. Radiat Oncol. 2019;14:18.PubMedPubMedCentral
64.
Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Engl J Med. 2015;373:1627–39.PubMedPubMedCentral
65.
Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017;18:895–903.PubMedPubMedCentral
66.
Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy LA, Lock MI, Rodrigues G, Yaremko BP, et al. Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial. Int J Radiat Oncol. 2018;102:S3–4.
67.
Chiba S, Saito A, Ogawa S, Takeuchi K, Kumano K, Seo S, Suzuki T, Tanaka Y, Saito T, Izutsu K, et al. Transplantation for accidental acute high-dose total body neutron- and γ-radiation exposure. Bone Marrow Transplant. 2002;29:935–9.PubMed
68.
Nagasawa H, Little JB. Induction of sister chromatid exchanges by extremely low doses of alpha-particles. Cancer Res. 1992;52:6394–6.PubMed
69.
Khan MA, Van Dyk J, Yeung IWT, Hill RP. Partial volume rat lung irradiation; assessment of early DNA damage in different lung regions and effect of radical scavengers. Radiother Oncol. 2003;66:95–102.PubMed
70.
Subhashree M, Venkateswarlu R, Karthik K, Shangamithra V, Venkatachalam P. DNA damage and the bystander response in tumor and normal cells exposed to X-rays. Mutat Res Toxicol Environ Mutagen. 2017;821:20–7.
71.
Pouget J-P, Georgakilas AG, Ravanat J-L. Targeted and off-target (Bystander and Abscopal) effects of radiation therapy: redox mechanisms and risk/benefit analysis. Antioxid Redox Signal. 2018;29:1447–87.PubMedPubMedCentral
72.
Astrahan M. BED calculations for fractions of very high dose: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2007; 69: S623–S624). Int J Radiat Oncol. 2008;71:963.
73.
Fowler JF. Linear quadratics is alive and well: in regard to Park et al. (Int J Radiat Oncol Biol Phys 2008; 70: 847–852). Int J Radiat Oncol. 2008;72:957.
74.
Kirkpatrick JP, Brenner DJ, Orton CG. The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Med Phys. 2009;36:3381–4.PubMed
75.
Andisheh B, Edgren M, Belkić D, Mavroidis P, Brahme A, Lind BK. A comparative analysis of radiobiological models for cell surviving fractions at high doses. Technol Cancer Res Treat. 2013;12:183–92.PubMed
76.
Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol. 2014;88:254–62.
77.
Song CW, Kim M-S, Cho LC, Dusenbery K, Sperduto PW. Radiobiological basis of SBRT and SRS. Int J Clin Oncol. 2014;19:570–8.PubMed
78.
Greco C, Zelefsky MJ, Lovelock M, Fuks Z, Hunt M, Rosenzweig K, Zatcky J, Kim B, Yamada Y. Predictors of local control after single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases. Int J Radiat Oncol. 2011;79:1151–7.
79.
Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, Mechalakos J, Zatcky J, Fuks Z, Yamada Y. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol. 2012;82:1744–8.
80.
Yamada Y, Bilsky MH, Lovelock DM, Venkatraman ES, Toner S, Johnson J, Zatcky J, Zelefsky MJ, Fuks Z. High-dose, single-fraction image-guided intensity-modulated radiotherapy for metastatic spinal lesions. Int J Radiat Oncol. 2008;71:484–90.
81.
Bodo S, Campagne C, Thin TH, Higginson DS, Vargas HA, Hua G, Fuller JD, Ackerstaff E, Russell J, Zhang Z, et al. Single-dose radiotherapy disables tumor cell homologous recombination via ischemia/reperfusion injury. J Clin Invest. 2019;129:786–801.PubMedPubMedCentral
82.
Shuryak I, Carlson DJ, Brown JM, Brenner DJ. High-dose and fractionation effects in stereotactic radiation therapy: analysis of tumor control data from 2965 patients. Radiother Oncol. 2015;115:327–34.PubMed
83.
Shibamoto Y, Miyakawa A, Otsuka S, Iwata H. Radiobiology of hypofractionated stereotactic radiotherapy: what are the optimal fractionation schedules? J Radiat Res. 2016;57:i76–82.PubMedPubMedCentral
84.
Ko EC, Benjamin KT, Formenti SC. Generating antitumor immunity by targeted radiation therapy: role of dose and fractionation. Adv Radiat Oncol. 2018;3:486–93.PubMedPubMedCentral
85.
86.
Weiner AB, Ko OS, Zhu A, Spratt DE, Hu JC, Schaeffer EM. National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer. Urol Oncol Semin Orig Investig. 2019;37:353.e1–8.
87.
Lewis S, Murthy V, Mahantshetty U, Shrivastava SK. Incidental dose to pelvic nodes in bladder-only radiotherapy: is it clinically relevant? Technol Cancer Res Treat. 2017;16:382–7.PubMedPubMedCentral
88.
Van Houtte P, Roelandts M, Mornex F. Radiotherapy of lung cancer: any room left for elective mediastinal irradiation in 2011? Cancer Radiothér. 2011;15:509–13.PubMed
89.
Woolf DK, Slotman BJ, Faivre-Finn C. The current role of radiotherapy in the treatment of small cell lung cancer. Clin Oncol. 2016;28:712–9.
90.
Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, et al. Modern radiation therapy for hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol. 2014;89:854–62.
91.
Pollack A., Karrison T, Balogh A. 2018 ASTRO Annual Meeting Late-breaking Abstract Selection LBA5 Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the NRG Oncology/RTOG 0534 SPPORT trial. Int J Radiat Oncol Biol Phys. 2018;102(5):1605. https://​doi.​org/​10.​1016/​j.​ijrobp.​2018.​08.​052.CrossRef
92.
Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28.PubMedPubMedCentral
93.
Thorsen LBJ, Offersen BV, Danø H, Berg M, Jensen I, Pedersen AN, Zimmermann SJ, Brodersen H-J, Overgaard M, Overgaard J. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34:314–20.PubMed
94.
Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, Kitamura H, Nishimura T. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 2010;70:2697–706.PubMed
95.
Zhang X, Niedermann G. Abscopal effects with hypofractionated schedules extending into the effector phase of the tumor-specific T-cell response. Int J Radiat Oncol. 2018;101:63–73.
96.
Marciscano AE, Ghasemzadeh A, Nirschl TR, Theodros D, Kochel CM, Francica BJ, Muroyama Y, Anders RA, Sharabi AB, Velarde E, et al. Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy. Clin Cancer Res. 2018;24:5058–71.PubMedPubMedCentral
97.
Lee M-H, Lee K-M, Kim E-H. Neighbor effect: penumbra-dose exposed neighbor cells contribute to the enhanced survival of high-dose targeted cells. Int J Radiat Biol. 2017;93:1227–38.PubMed
98.
Butterworth KT, McGarry CK, Trainor C, O’Sullivan JM, Hounsell AR, Prise KM. Out-of-field cell survival following exposure to intensity-modulated radiation fields. Int J Radiat Oncol. 2011;79:1516–22.
99.
McGarry CK, Butterworth KT, Trainor C, McMahon SJ, O’Sullivan JM, Prise KM, Hounsell AR. In-vitro investigation of out-of-field cell survival following the delivery of conformal, intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) plans. Phys Med Biol. 2012;57:6635–45.PubMed
100.
Trainor C, Butterworth KT, McGarry CK, McMahon SJ, O’Sullivan JM, Hounsell AR, Prise KM. DNA damage responses following exposure to modulated radiation fields. PLoS One. 2012;7:e43326.PubMedPubMedCentral
101.
Diamant A, Chatterjee A, Faria S, El Naqa I, Bahig H, Filion E, Robinson C, Al-Halabi H, Seuntjens J. Can dose outside the PTV influence the risk of distant metastases in stage I lung cancer patients treated with stereotactic body radiotherapy (SBRT)? Radiother Oncol. 2018;128:513–9.PubMed
102.
Fowler JF, Welsh JS, Howard SP. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol. 2004;59:242–9.
103.
Wang JZ, Li XA, D’Souza WD, Stewart RD. Impact of prolonged fraction delivery times on tumor control: a note of caution for intensity-modulated radiation therapy (IMRT). Int J Radiat Oncol Biol Phys. 2003;57:543–52.PubMed
104.
Zheng X-K, Chen L-H, Yan X, Wang H-M. Impact of prolonged fraction dose-delivery time modeling intensity-modulated radiation therapy on hepatocellular carcinoma cell killing. World J Gastroenterol. 2005;11:1452–6.PubMedPubMedCentral
105.
Zheng X-K, Chen L-H, Wang W-J, Ye F, Liu J-B, Li Q-S, Sun H-W. Impact of prolonged fraction delivery times simulating IMRT on cultured nasopharyngeal carcinoma cell killing. Int J Radiat Oncol. 2010;78:1541–7.
106.
Viani GA, Viana BS, Martin JEC, Rossi BT, Zuliani G, Stefano EJ. Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer. 2016;122:2004–11.PubMed
107.
Shimizuguchi T, Nihei K, Okano T, Machitori Y, Ito K, Karasawa K. A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Int J Clin Oncol. 2017;22:373–9.PubMed
108.
Yao Q, Zheng R, Xie G, Liao G, Du S, Ren C, Li R, Lin X, Hu D, Yuan Y. Late-responding normal tissue cells benefit from high-precision radiotherapy with prolonged fraction delivery times via enhanced autophagy. Sci Rep. 2015;5:9119.PubMedPubMedCentral
109.
Slatkin DN, Spanne P, Dilmanian FA, Gebbers JO, Laissue JA. Subacute neuropathological effects of microplanar beams of x-rays from a synchrotron wiggler. Proc Natl Acad Sci USA. 1995;92:8783–7.PubMedPubMedCentral
110.
Laissue JA, Blattmann H, Slatkin DN. Alban Köhler (1874-1947): Erfinder der Gittertherapie. Z Med Phys. 2012;22:90–9.PubMed
111.
Peñagarícano JA, Moros EG, Ratanatharathorn V, Yan Y, Corry P. Evaluation of spatially fractionated radiotherapy (GRID) and definitive chemoradiotherapy with curative intent for locally advanced squamous cell carcinoma of the head and neck: initial response rates and toxicity. Int J Radiat Oncol. 2010;76:1369–75.
112.
Gao M, Mohiuddin MM, Hartsell WF, Pankuch M. Spatially fractionated (GRID) radiation therapy using proton pencil beam scanning (PBS): feasibility study and clinical implementation. Med Phys. 2018;45:1645–53.PubMed
113.
Prezado Y, Jouvion G, Hardy D, Patriarca A, Nauraye C, Bergs J, González W, Guardiola C, Juchaux M, Labiod D, et al. Proton minibeam radiation therapy spares normal rat brain: long-term clinical, radiological and histopathological analysis. Sci Rep. 2017;7:14403.PubMedPubMedCentral
114.
Dilmanian FA, Button TM, Le Duc G, Zhong N, Pena LA, Smith JAL, Martinez SR, Bacarian T, Tammam J, Ren B, et al. Response of rat intracranial 9L gliosarcoma to microbeam radiation therapy. Neuro Oncol. 2002;4:26–38.PubMedPubMedCentral
115.
Asur R, Butterworth KT, Penagaricano JA, Prise KM, Griffin RJ. High dose bystander effects in spatially fractionated radiation therapy. Cancer Lett. 2015;356:52–7.PubMed
116.
117.
Prezado Y, Jouvion G, Patriarca A, Nauraye C, Guardiola C, Juchaux M, Lamirault C, Labiod D, Jourdain L, Sebrie C, et al. Proton minibeam radiation therapy widens the therapeutic index for high-grade gliomas. Sci Rep. 2018;8:16479.PubMedPubMedCentral
118.
Prezado Y, Jouvion G, Guardiola C, Gonzalez W, Juchaux M, Bergs J, Nauraye C, Labiod D, De Marzi L, Pouzoulet F, et al. Tumor control in RG2 glioma-bearing rats: a comparison between proton minibeam therapy and standard proton therapy. Oncol: Int J Radiat; 2019.
119.
Smyth LML, Donoghue JF, Ventura JA, Livingstone J, Bailey T, Day LRJ, Crosbie JC, Rogers PAW. Comparative toxicity of synchrotron and conventional radiation therapy based on total and partial body irradiation in a murine model. Sci Rep. 2018;8:12044.PubMedPubMedCentral
120.
Goedegebuure RSA, de Klerk LK, Bass AJ, Derks S, Thijssen VLJL. Combining radiotherapy with anti-angiogenic therapy and immunotherapy; a therapeutic triad for cancer? Front Immunol. 2019;9:3107.PubMedPubMedCentral
121.
Carvalho H, Villar R. Radiotherapy and immune response: the systemic effects of a local treatment. Clinics. 2018;73:e557s.PubMed
Metadata
Title
Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy
Authors
M. Protopapa
V. Kouloulias
A. Kougioumtzopoulou
Z. Liakouli
C. Papadimitriou
A. Zygogianni
Publication date
01-04-2020
Publisher
Springer International Publishing
Keyword
Radiotherapy
Published in
Clinical and Translational Oncology / Issue 4/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02165-0

Other articles of this Issue 4/2020

Clinical and Translational Oncology 4/2020 Go to the issue

Research Article

ILC3 cells promote the proliferation and invasion of pancreatic cancer cells through IL-22/AKT signaling

Research Article

Breast cancer and cytomegalovirus

Research Article

Evaluation of axillary lymph node metastasis burden by preoperative ultrasound in early-stage breast cancer with needle biopsy-proven metastasis

Research Article

Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy

Research Article

Human colorectal cancer derived-MSCs promote tumor cells escape from senescence via P53/P21 pathway

Research Article

Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits